Skip to main content
JINGHUA PHARMACEUTICAL GROUP CO., LTD. logo

JINGHUA PHARMACEUTICAL GROUP CO., LTD. — Investor Relations & Filings

Ticker · 002349 ISIN · CNE100000L14 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,684 across all filing types
Latest filing 2026-05-20 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002349

About JINGHUA PHARMACEUTICAL GROUP CO., LTD.

https://www.ntjhzy.com

Jinghua Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company’s portfolio encompasses traditional Chinese medicines (TCM), chemical active pharmaceutical ingredients (APIs), and finished chemical preparations. Key products include renowned traditional formulations such as Wangshi Baochi Wan and Ji Desheng Sheyao, alongside essential APIs like Phenobarbital and Primidone. The group operates multiple manufacturing bases equipped with advanced production lines and maintains rigorous quality control standards. By integrating traditional medicinal heritage with modern pharmaceutical technology, the company serves both domestic and international healthcare markets, focusing on therapeutic areas such as digestive health, emergency medicine, and neurological treatments.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is an announcement by 精华制药集团股份有限公司 detailing the implementation of the 2025 equity distribution (dividend) plan: it specifies the dividend per share, total dividend amount, record date, ex-dividend date, distribution method, and tax treatment for different shareholders. This fits the definition of a Notice of Dividend Amount (DIV).
2026-05-20 Chinese
2025年年度股东会法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm on the legality of convening and conducting the 2025 Annual General Meeting, including detailed vote counts. There is no specific category for external legal opinions and it is not the company’s primary notice or report itself (e.g., not an Annual Report, Interim Report, or Dividend Notice). Although vote results are included, it is not an official company resolution announcement but a compliance/legal opinion. Therefore it falls under the general Regulatory Filings (RNS) fallback category.
2026-05-14 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement of the resolutions and detailed vote counts of the 2025 Annual General Shareholders’ Meeting (including approval/rejection/abstention percentages for each proposal). It is not the full meeting materials or financial statements but the official declaration of voting results at the AGM. This matches the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-14 Chinese
关于2025年限制性股票激励计划预留授予登记完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from a company about the completion of the registration of a reserved grant of restricted stock under a 2025 restricted stock incentive plan. It details the approval process, the number of shares granted, the price, the recipients, the lock-up periods, performance conditions, and the impact on financials. It is a formal disclosure related to a stock-based incentive plan, including share issuance and capital changes. The document is not a full financial report, earnings release, or management discussion, but rather a specific announcement about a share-based incentive plan and related share issuance. This fits best under the category of Share Issue/Capital Change (SHA), as it involves issuance of new shares to incentive plan participants and changes in share capital structure.
2026-05-07 Chinese
关于调整公司2025年限制性股票激励计划相关事项的公告
Remuneration Information Classification · 85% confidence The document is an official announcement by the company’s board regarding adjustments to its 2025 restricted stock incentive (equity compensation) plan, including details on decision procedures, price adjustments due to dividends, committee and legal opinions. It is not a full financial report or dividend notice, nor is it a simple regulatory update; it directly concerns executive/share incentive remuneration. This matches the Remuneration Information category (DEF 14A).
2026-04-22 Chinese
2025年度非经营性资金占用及其他关联方占用资金往来情况的专项报告
Audit Report / Information Classification · 87% confidence The document is a special audit report (专项报告) issued by an external accounting firm (BDO China Shu Lun Pan) on non-operating fund occupation and related-party fund transactions for the 2025 financial year. It includes audit procedures, reconciliations with audited financial statements, signed by certified public accountants, and is not a full annual report or simple announcement. This matches the definition of a standalone audit report (AR).
2026-04-22 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.